Development of a graphite probe calorimeter for absolute clinical dosimetry.

The aim of this work is to present the numerical design optimization, construction, and experimental proof of concept of a graphite probe calorimeter (GPC) conceived for dose measurement in the clinical environment (U.S. provisional patent 61∕652,540).

Sci-Sat AM: Brachy - 03: Feasibility study of the determination of absorbed dose to water using a fricke based system.

By measuring the dose to water directly a metrology standard, independent of air kerma, can be developed to make the basis of HDR brachytherapy dosimetry consistent with current dosimetry methods for external radiation beams. The Fricke dosimeter system, a liquid chemical dosimeter, provides a means of measuring the absorbed dose rate to water directly by measuring the radiation-induced change in absorption of the Fricke solution. In an attempt to measure the absorbed dose to water directly for a Ir HDR brachytherapy source a ring shaped Fricke holder was constructed from PMMA, essentially following the work of Austerlitz et al.

Sci-Thur PM: YIS - 09: Development of a graphite probe calorimeter for absolute clinical dosimetry: Numerical design optimization, prototyping and experimental proof-of-concept.

In this work, the feasibility of absolute dose to water measurements using a small-scale graphite probe calorimeter (GPC) in a clinical environment is established. A numerical design optimization study was conducted by simulating the heat transfer in the GPC resulting from irradiation using a finite element method software package. The choice of device shape, dimensions and materials was made to minimize the heat loss in the sensitive volume of the GPC.

Information for genetic management of mtDNA disease: sampling pathogenic mtDNA mutants in the human germline and in placenta.

Background: Families with a child who died of severe, maternally inherited mitochondrial DNA (mtDNA) disease need information on recurrence risk. Estimating this risk is difficult because of (a) heteroplasmy-the coexistence of mutant and normal mtDNA in the same person-and (b) the so-called mitochondrial bottleneck, whereby the small number of mtDNAs that become the founders for the offspring cause variation in dose of mutant mtDNA. The timing of the bottleneck and of segregation of mtDNA during foetal life determines the management options.

Mosaicism for mitochondrial DNA polymorphic variants in placenta has implications for the feasibility of prenatal diagnosis in mtDNA diseases.

Women who have had a child with mitochondrial DNA (mtDNA) disease need to know the risk of recurrence, but this risk is difficult to estimate because mutant and wild-type (normal) mtDNA coexist in the same person (heteroplasmy). The possibility that a single sample may not reflect the whole organism both impedes prenatal diagnosis of most mtDNA diseases, and suggests radical alternative strategies such as nuclear transfer. We used naturally occurring mtDNA variants to investigate mtDNA segregation in placenta.